These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22231340)

  • 1. Suicide without depression after withdrawal of a dopamine agonist in a patient with Parkinson's disease.
    Flament M; Loas G; Godefroy O; Krystkowiak P
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):E32. PubMed ID: 22231340
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson's disease surgery.
    Nirenberg MJ
    Brain; 2010 Nov; 133(11):e155; author reply e156. PubMed ID: 20659959
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopamine agonist withdrawal syndrome in Parkinson's disease.
    Solla P; Fasano A; Cannas A; Marrosu F
    J Neurol Sci; 2017 Nov; 382():47-48. PubMed ID: 29111017
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.
    Thobois S; Ardouin C; Lhommée E; Klinger H; Lagrange C; Xie J; Fraix V; Coelho Braga MC; Hassani R; Kistner A; Juphard A; Seigneuret E; Chabardes S; Mertens P; Polo G; Reilhac A; Costes N; LeBars D; Savasta M; Tremblay L; Quesada JL; Bosson JL; Benabid AL; Broussolle E; Pollak P; Krack P
    Brain; 2010 Apr; 133(Pt 4):1111-27. PubMed ID: 20237128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suicide attempt in a dopamine agonist withdrawal syndrome in Parkinson's disease.
    Espindola M; Rojas NG; Vaisentein G; Da Prat G; Cesarini M; Etcheverry JL; Gatto EM
    Parkinsonism Relat Disord; 2024 Apr; 121():106017. PubMed ID: 38401377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson's disease.
    Cunnington AL; White L; Hood K
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1051-2. PubMed ID: 22677468
    [No Abstract]   [Full Text] [Related]  

  • 7. Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up.
    Lang AE; Kleiner-Fisman G; Saint-Cyr JA; Miyasaki J; Lozano A
    Neurology; 2003 Jan; 60(1):154-5; author reply 154-5. PubMed ID: 12525751
    [No Abstract]   [Full Text] [Related]  

  • 8. Dopamine agonist withdrawal syndrome in Parkinson disease.
    Rabinak CA; Nirenberg MJ
    Arch Neurol; 2010 Jan; 67(1):58-63. PubMed ID: 20065130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up.
    Houeto JL; Mesnage V; Welter ML; Mallet L; Agid Y; Bejjani BP
    Neurology; 2003 Jan; 60(1):154-5; author reply 154-5. PubMed ID: 12530402
    [No Abstract]   [Full Text] [Related]  

  • 10. Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel.
    Solla P; Cannas A; Marrosu MG; Marrosu F
    Parkinsonism Relat Disord; 2015 Nov; 21(11):1383-4. PubMed ID: 26453388
    [No Abstract]   [Full Text] [Related]  

  • 11. A Man With Persistent Dopamine Agonist Withdrawal Syndrome After 7 Years Being Off Dopamine Agonists.
    Huynh NT; Sid-Otmane L; Panisset M; Huot P
    Can J Neurol Sci; 2016 Nov; 43(6):859-860. PubMed ID: 26842385
    [No Abstract]   [Full Text] [Related]  

  • 12. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center.
    Patel S; Garcia X; Mohammad ME; Yu XX; Vlastaris K; O'Donnell K; Sutton K; Fernandez HH
    J Neurol Sci; 2017 Aug; 379():308-311. PubMed ID: 28716269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine agonist withdrawal syndrome: A comprehensive review.
    Yu XX; Fernandez HH
    J Neurol Sci; 2017 Mar; 374():53-55. PubMed ID: 28104232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease.
    Kimber TE; Thompson PD; Kiley MA
    J Clin Neurosci; 2008 Feb; 15(2):205-8. PubMed ID: 18068992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychiatric effects of Parkinson's disease treatment.
    Aarons S; Peisah C; Wijeratne C
    Australas J Ageing; 2012 Sep; 31(3):198-202. PubMed ID: 22950594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
    Joutsa J; Martikainen K; Vahlberg T; Kaasinen V
    Parkinsonism Relat Disord; 2012 Dec; 18(10):1079-83. PubMed ID: 22784693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer risks among the users of ergot-derived dopamine agonists for Parkinson's disease, a nationwide population-based survey.
    Wang V; Chao TH; Hsieh CC; Lin CC; Kao CH
    Parkinsonism Relat Disord; 2015 Jan; 21(1):18-22. PubMed ID: 25457814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine agonist switching in Parkinson's disease.
    Stewart D; Morgan E; Burn D; Grosset D; Chaudhuri KR; MacMahon D; Needleman F; Macphee G; Heywood P
    Hosp Med; 2004 Apr; 65(4):215-9. PubMed ID: 15127675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.
    Ceravolo R; Rossi C; Del Prete E; Bonuccelli U
    Expert Opin Drug Saf; 2016; 15(2):181-98. PubMed ID: 26646536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.